TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32589775
Drug: Remdesivir (RDV)
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir (RDV) single-dose i.v. administration over 2 hours (dose range 3-225 mg)
Study: 32589775
Drug: Remdesivir (RDV)
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir (RDV) solution and lyophilized formulations
Study: 34128526
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX) injections
Study: 32078256
Drug: rIX-FP infusions
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIX-FP infusions
Study: 32567290
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin A and D supplementation
Study: 32475359
Drug: Fragmented +
Normalized name: palmitoyl fragment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmented + Coffee (300 mg caffeine)
Study: 32475359
Drug: Fragmented (waking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmented (waking hourly for 5 min)
Study: 32534628
Drug: Adjuvanted AGS-v
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvanted AGS-v vaccine (200 nmol with Montanide ISA 51)
Study: 32534628
Drug: Vaccine only
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine only AGS-v (200 nmol)
Study: 36376023
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IVMP) pulse for 3 months
Study: 36376023
Drug: Antiseizure medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseizure medication (ASM) only
Study: 32199926
Drug: Routine prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine prescription of 28 tablets of oxycodone 5 mg
Study: 32199926
Drug: Reduced prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced prescription of 5 tablets of oxycodone 5 mg
Study: 33137600
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) alone
Study: 33137600
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) then Behavioural Activation Therapy (BA) for MDD
Study: 33137600
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation Therapy (BA) then Cognitive Processing Therapy (CPT)
Study: 35766588
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (diode laser 940 nm, 31.7 J/cm2 energy density, 1.7 cm2 spot size, 300 mW power, continuous-wave, contact mode)
Study: 32366992
Drug: Topical rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical rifampicin irrigation
Study: 32366992
Drug: Topical rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical rifampicin
Study: 35139574
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist administration the day after hCG triggering
Study: 33216113
Drug: Nebulized PC786
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized PC786 (5 mg)
Study: 32757038
Drug: Rhino-Protect ointment
Normalized name: petrolatum Topical Ointment [Lantiseptic Protective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhino-Protect ointment
Study: 33371086
Drug: Continuous nursing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nursing treatment scheme based on Omaha system (OS)
Study: 33371086
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment including general guidance associated with PD and outpatient telephone calls from clinical nurses
Study: 35241538
Drug: Carboplatin AUC2
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC2 and Paclitaxel (45 mg/m2)
Study: 33662760
Drug: L-menthol mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol mouth rinse (MENT)
Study: 33068301
Drug: Traditional antidiabetic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antidiabetic therapy (Control, n=40)
Study: 36194619
Drug: Oral Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Itraconazole 100 mg/day and topical Terbinafine hydrochloride 1%
Study: 32965622
Drug: Sexual intercourse
Normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual intercourse 3–4 times/week with symptomatic treatment
Study: 32965622
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment only, no sexual intercourse or masturbation
Study: 32795778
Drug: 15-mg apomorphine
Normalized name: apomorphine hydrochloride 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg apomorphine sublingual film (APL)
Study: 32795778
Drug: 2-mg subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg subcutaneous Apo-go
Study: 35119481
Drug: Lenvatinib once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib once daily plus pembrolizumab every 6 weeks plus TACE
Study: 35045888
Drug: Ionic-iodine polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic-iodine polymer complex (200 mg of elemental iodine) in encapsulated form
Study: 35045888
Drug: Ionic-iodine polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic-iodine polymer complex (200 mg of elemental iodine) in suspension syrup form
Study: 35045888
Drug: Ionic-iodine polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic-iodine polymer complex (200 mg of elemental iodine) in throat spray form
Study: 32682395
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine wound infusion by PCA pump
Study: 32682395
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline wound infusion by PCA pump (Control)
Study: 34706172
Drug: Risankizumab (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (90 mg, subcutaneously once every 4 weeks)
Study: 33948911
Drug: Atogepant (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant (60 mg) co-administered with Acetaminophen (1000 mg)
Study: 33948911
Drug: Atogepant (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant (60 mg) co-administered with Naproxen (500 mg)
Study: 33948911
Drug: Atogepant co-administered
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atogepant co-administered with Acetaminophen
Study: 33948911
Drug: Atogepant co-administered
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atogepant co-administered with Naproxen
Study: 34384001
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + Rosuvastatin (10 or 20 mg) SPC
Study: 34384001
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg monotherapy
Study: 32091599
Drug: Low-nitrate vegetables
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-nitrate vegetables + placebo pills
Study: 32091599
Drug: Low-nitrate vegetables
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-nitrate vegetables + nitrate pills (300 mg nitrate)
Study: 32091599
Drug: Leafy green
Normalized name: Green tea leaf
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leafy green vegetables containing 300 mg nitrate + placebo pills
Study: 33035741
Drug: Nonstarters (compared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonstarters (compared to treatment starters)
Study: 34229085
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil inhalation for 15 min before dressing (Lavender‐15 Group)
Study: 34229085
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil inhalation for 60 min before dressing (Lavender‐60 Group)
Study: 34229085
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group inhaled jojoba (placebo) oil for 15 min before dressing
Study: 33932193
Drug: Endophytic fungi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endophytic fungi selected for L‐asparaginase (L‐ASNase) production test (20 isolates).
Study: 33932193
Drug: Phyllosticta catimbauensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllosticta catimbauensis URM 7672 for partial optimisation of L‐ASNase production.
Study: 33206039
Drug: Precision clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision clinical trial framework including treatment‐targeted enrichment, adaptive treatments, and precise measurement.
Study: 34189995
Drug: PRC-063 (Extended-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRC-063 (Extended-Release Methylphenidate)
Study: 32570811
Drug: Leucine-enriched protein
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-enriched protein supplement (leucine 3 g, protein mixture 17 g, vitamin D 800 IU, calcium 300 mg, fat 1.1 g, carbohydrate 2.5 g)
Study: 32570811
Drug: Isocaloric carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric carbohydrate supplement
Study: 36173236
Drug: Bionic Pancreas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionic Pancreas (BP) with insulin aspart or insulin lispro (N=107)
Study: 33796452
Drug: Trastuzumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab therapy
Study: 34343296
Drug: Metformin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin followed by glipizide and then insulin glargine on failure to achieve HbA1c < 6.5%
Study: 34343296
Drug: Initial triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial triple therapy with metformin/pioglitazone/exenatide
Study: 33778929
Drug: Etrolizumab 105
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab 105 mg by Autoinjector (AI)
Study: 33778929
Drug: Etrolizumab 105
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab 105 mg by Prefilled Syringe with Needle Safety Device (PFS‐NSD)
Study: 34974502
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of l-Citrulline (CIT)
Study: 33582575
Drug: Opioid receptor
Normalized name: Opioid receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid receptor antagonist naltrexone (NAL)
Study: 32619868
Drug: Sublingual buprenorphine-naloxone
Normalized name: buprenorphine / naloxone Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine-naloxone (BUP-NX)
Study: 33693835
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention (280 g whole blueberries and 12 g soluble fiber per day)
Study: 33494380
Drug: Transconjunctival injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transconjunctival injection of BTX‐A (3 units); n = 15, 25 eyes
Study: 33494380
Drug: Transcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous injection of BTX‐A (3 units); n = 16, 28 eyes
Study: 32955964
Drug: Herbarium mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbarium mixture (G. ulmifolia/T. stans) 400 mg before each meal for 90 days
Study: 33066862
Drug: Nardostachys jatamansi
Normalized name: Nardostachys chinensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nardostachys jatamansi (3 g total, 1 capsule 3 times a day for 4 weeks)
Study: 36299870
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical airway anesthesia induction strategy (aerosol inhalation airway anesthesia, subglottic airway anesthesia, and low-dose intravenous anesthetics)
Study: 36299870
Drug: Conventional induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional induction group (high-dose intravenous anesthetics)
Study: 36329428
Drug: PRP +
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP + Artz (2.5 ml, 10 mg/ml HA followed by 3 ml PRP)
Study: 36329428
Drug: PRP +
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP + HYAJOINT Plus (3 ml, 20 mg/ml cross‐linked HA followed by 3 ml PRP)
Study: 34629067
Drug: 50% calorie-restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% calorie-restricted and ketogenic diet combined with aerobic exercise during intravenous chemotherapy
Study: 32769919
Drug: LED photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED photobiomodulation therapy 3 times a week for 2 weeks
Study: 32769919
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy 3 times a week for 2 weeks
Study: 35283313
Drug: ChAdOx1 followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ChAdOx1 followed by an mRNA vaccine
Study: 35283313
Drug: Spike‐ACE2‐receptor‐blocking antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spike‐ACE2‐receptor‐blocking antibodies
Study: 32756845
Drug: MS/2 medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS/2 medium supplemented with 100 mg L‐1 of cysteine, 0.5 mg L‐1 of gibberellic acid (AG3) and 30 g L‐1 of sucrose
Study: 34812713
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (fluoxetine)
Study: 34812713
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and/or pharmacological treatment
Study: 33139781
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti-Toxoplasma gondii antibodies in MS patients
Study: 33139781
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti-Toxoplasma gondii antibodies in controls
Study: 35875890
Drug: Vutrisiran 25
Normalized name: VUTRISIRAN 25MG/0.5ML SOLN INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutrisiran 25 mg every 3 months (Q3M)
Study: 32881639
Drug: Post-discharge phone
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge phone calls from a navigator to review the recommended treatment plan and address barriers to engagement on days 3, 7, 14, and 21
Study: 32282720
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) and electronic moxibustion (EM) + alpha blocker
Study: 33317802
Drug: Physostigmine 0.5
Normalized name: physostigmine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 0.5 mg h−1 i.v. for 24 h
Study: 35341724
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (control group)
Study: 32200817
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy of external beam therapy
Study: 35546527
Drug: Everolimus regimen
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus regimen (low dose CNI, everolimus, and prednisolone)
Study: 35119460
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of visual campaign and narrative vignette from the perspective of a patient with OUD
Study: 35119460
Drug: Combined visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined visual campaign and patient vignette about the value of medication treatment for OUD
Study: 34520219
Drug: VRD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRD treatment
Study: 32799981
Drug: Prescriptions for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions for children under five years
Study: 34907041
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE)
Study: 34907041
Drug: Comprehensive internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive internal medical treatment (as part of the trial group)
Study: 34907041
Drug: Comprehensive internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive internal medical treatment (control group)
Study: 36701139
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg)
Study: 34991130
Drug: Zishen Yutai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zishen Yutai Pill
Study: 32340780
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (general reference)
Study: 34228127
Drug: Counseling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling plus nicotine replacement therapy (NRT)
Study: 32857992
Drug: 1 +
Normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 + 1 dosing schedule of PCV13 (6w + 1 and 14w + 1 groups)
Study: 32857992
Drug: 1 +
Normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 + 1 dosing schedule of PCV10 (6w + 1 and 14w + 1 groups)
Study: 32857992
Drug: 2 +
Normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 + 1 dosing schedule of PCV13
Study: 32857992
Drug: 2 +
Normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 + 1 dosing schedule of PCV10
Study: 35260448
Drug: Intensive Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Nutrition Therapy
Study: 32513192
Drug: Habit-forming interventions
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit-forming interventions (e.g., having a relative ask about pill-taking, re-packaging medications, leaving medications in view, using alarms, carrying water, linking pill-taking to radio/prayer schedules)
Study: 33891348
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly (675/225/225 mg)
Study: 33849494
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of oat bran daily for 4 weeks at lunch and dinner
Study: 32296094
Drug: Compeed Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compeed Patches
Study: 32296094
Drug: Zovirax Cream
Normalized name: acyclovir Topical Cream [Zovirax]
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zovirax Cream (5% acyclovir)
Study: 33037518
Drug: Getong Tongluo
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Getong Tongluo Capsule (GTC) 250 mg plus EGB-matching placebo 40 mg (GTC group)
Study: 33037518
Drug: EGB 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGB 40 mg plus GTC-matching placebo 250 mg (EGB group)
Study: 33037518
Drug: GTC-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTC-matching placebo 250 mg plus EGB-matching placebo 40 mg (Placebo group)
Study: 33037518
Drug: Getong Tongluo
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Getong Tongluo Capsule (GTC) 250 mg
Study: 33037518
Drug: EGB 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGB 40 mg
Study: 35629000
Drug: Anti-disgust cognitive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-disgust cognitive behavioral therapy (AD-CBT)
Study: 32716603
Drug: Oral irrigator
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigator with 0.06% CHX solution
Study: 32716603
Drug: Oral irrigator
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigator with water
Study: 32716603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hygiene instruction and mechanical debridement)
Study: 32668456
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg albendazole
Study: 32016292
Drug: Filgotinib, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib, 200 mg
Study: 32016292
Drug: Filgotinib, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib, 100 mg
Study: 34236303
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg phentermine
Study: 34236303
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg phentermine
Study: 34236303
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg and 30 mg phentermine
Study: 35924312
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy (iCBT)